Humana Adds Two Independent Directors — HUM Board Update

This board expansion occurs against a backdrop of strategic and regulatory developments already disclosed by Humana through 2025 and into 2026. Relevant prior events and context include: - Regulatory and litigation matters: ongoing RADV audits and rulemaking (company sued HHS in September 2023), a challenge to CMS' 2025 Star Ratings methodology (October 2024), and DOJ subpoenas concerning Medicare risk adjustment coding practices. - Strategic moves: the company completed a primary care acquisition in February 2026 for $941 million and continues to grow CenterWell (pharmacy and primary care services) as part of a consumer-centered integrated-care strategy. All CMS contracts were renewed for 2026 per company disclosures. - Financial and operational trends: 2025 Insurance segment premiums/services were concentrated in Medicare (Total Medicare $106,261 million; 82.6% of consolidated premiums/services), with 2025 net income of $1,188 million and a dividend of $3.54 per share. The company has acknowledged medical cost trends and membership volatility in certain product lines (e.g., a 19.8% year-over-year PDP decline and exit from fully-insured commercial business disclosed in filings). Taken together, the addition of two independent directors on 2026-07-29 aligns with heightened governance needs tied to Humana's regulatory exposures, CenterWell expansion and heavy Medicare concentration. Investors should look for follow-up disclosures on director backgrounds, committee roles and any board-level responses to the company's principal risks.